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Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder uniformly characterized by the production of autoantibodies directed against a host of cellular proteins. Several of these autoantibodies have been associated with specific clinical entities and are associated with direct tissue injury. Both genetic and environmental factors contribute to disease pathogenesis. Evidence of genetic contribution comes from a high concordance rate among monozygotic twins compared with dizygotic twins, 2 familial aggregation, the known associated genetic polymorphisms and the evidence of linkage at multiple loci in several genome wide scans.
The hallmark of this systemic disease is the production of autoantibodies against nuclear constituents, particularly the spliceosome and double-stranded DNA. 3 Of the maladies of modern man, SLE is unusually heterogenous with a wide range of clinical severity and of 3 An individual lupus patient's serum may bind one or more of the cellular constituents now known to be bound by lupus autoantibodies.
Various antinuclear antibody patterns are common among SLE patients, such as nuclear speckled, nuclear homogeneous and rim patterns. Although 35% of patients with antinucleolar antibodies have SLE, overall, the nucleolar pattern of antinuclear antibody immunofluorescence is actually uncommon among lupus patients, perhaps, as infrequent as 3%. 6 In this study we stratified pedigrees multiplex for lupus by whether they have a nucleolar antinuclear antibody pattern in one or more of their lupus affecteds. A genome scan on this subset of pedigrees multiplex for lupus showed sufficiently strong evidence to establish linkage at chromosome 11q14, with a LOD max = 5.62 in African-American pedigrees.
Results

Clinical associations
There were a total of 28 SLE patients who had a nucleolar immunofluorescence pattern, of which 15 were Euro-pean-American, 12 were African-American and one was Native-American. Clinical associations with the ACR criteria in this subset of SLE patients was compared to a control group, matched for sex and race, who did not show nucleolar antinuclear antibody patter. There was no statistically significant difference in the association with the ACR criteria between the cases and the control group.
Interestingly, SLE patients with a nucleolar antinuclear antibody pattern did not have a higher frequency of Raynaud's phenomenon nor sclerodactyly when compared with controls. An anti-topoisomerase-I antibody test was performed using a solid phase immunosorbant assay (Wampole Laboratories, Cranbury, NJ, USA) for all patients who had a nucleolar staining pattern, and they all tested negative.
Linkage results
Genetic linkage of familial SLE characterized by nucleolar immunofluorescence pattern were assessed using six screening models of inheritance. 7 Microsatellite genotyping data at 307 loci were used to screen with two-point LOD scores using a maximum likelihood model-based linkage analysis. A LOD score of 5.07 was obtained for marker D11S2002 on chromosome 11q14 among families of African-American heritage. This LOD score exceeds the accepted threshold of established linkage. 8 This effect was then maximized to LOD = 5.62 using a dominant model of inheritance, a disease frequency of 0.07, 100% homogeneity, and penetrance values of 95% and 99% for males and females, respectively ( Figure 1 ).
Multipoint analysis produced a maximum LOD score (LOD multi = 4.64) at 82 centiMorgans (cM) from the p telomere of chromosome 11 using the same dominant model ( Figure 2 ). To further verify the presence of a linkage effect in the genomic neighborhood of D11S2002 we genotyped two additional markers, D11S937 and D11S1887, which are 5.5 cM centromeric and 6 cM telomeric to D11S2002, respectively. Results validated linkage to this region with a LOD = 4.86 and LOD = 2.93 for markers D11S937 and D11S1887 respectively, using a dominantly inherited model with 92% penetrance in females and 49% penetrance in males. Other effects that surpassed the threshold for suggestive linkage (LOD Ͼ 1.9) are summarized in Table 1 . 8 This effect was maximized with a dominant model with 95% penetrance in males and 99% in females. ALL = All pedigrees; EA = EuropeanAmerican pedigrees; AA = African-American pedigrees.
Discussion
Significant progress has been made in the identification of SLE susceptibility genes using modern genetic methods. A number of candidate loci have been identified including complement components genes, Fc␥ receptors and various HLA alleles. 9 Several genome-wide scans revealed evidence for linkage of SLE to multiple loci in the human genome. 9 In previously published studies, significant linkages with a LOD у 3.3 have been established at 1q22-23, 1q41, 2q37, 4p16, 6p21-11, 16q13, and 17p13. 7, [10] [11] [12] [13] [14] [15] In this study, we selected SLE pedigrees based on the presence of antinucleolar antibodies and found evidence for linkage at 11q14, where SLEH1 was already known to reside 1 (http://www.gene. ucl.ac.uk/cgi-bin/nomenclature/choose.pl?match=SLEH1). These results show that stratifying lupus multiplex families based on the presence of a common immunologic feature increases the genetic homogeneity and, thus, increases the strength of the linkage signals detected.
We identified a significant linkage effect to SLE in African-American pedigrees at 11q14 at D11S2002 with a maximum LOD score of 5.62. This result is sufficiently powerful to establish the presence of an SLE suscepti-bility gene in this area of the human genome. Our twopoint analyses suggest a dominant model of inheritance with penetrance values of 95% in males and 99% in females.
This effect was further supported by multipoint linkage analysis on chromosome 11, where the highest screening LOD score was 4.64 using the same dominant model at 82 cM from the p telomere of chromosome 11, which corresponds to the position of marker D11S2002. Genotyping of two additional markers within 6 cM from marker D11S2002 provided additional evidence of significant linkage to this region. The absence of similar effects in the European-American pedigrees suggests that the gene responsible for the linkage in African-Americans is probably not relevant to SLE in European-Americans.
We also found several additional genetic effects that exceed the level for suggestive linkage (LOD Ͼ 1.9), (Table 1) , however the importance of these effects cannot be gauged until additional collections of pedigrees are tested to confirm and refine these possible linkages.
Antinucleolar antibodies react to several known nucleolar antigens including RNA polymerase I, PM-Scl, fibrillarin, TO (or Th), NOR-90, nucleophosmin and nucleolin. Their presence is mostly correlated with scleroderma or related conditions such as primary Raynaud's phenomenon. 16 Anti-nucleolin and anti-NOR-90 antibodies are seen in some patients with SLE. 16 In addition, recent studies in the MRL/lpr and NZB/NZW F1 lupusprone mice suggest that nucleolin is a major and the first target of the earliest autoimmune response in these animal models of SLE. 17 The overall significance of these autoantibodies in these African-American pedigrees, however, is yet to be determined.
Our patients did not show an increased frequency of features suggesting scleroderma (sclerodactyly or Raynaud's) when compared with controls. This probably eliminates an overlap syndrome being a consideration for the clinical features of their SLE. In addition, we did not find anti-topoisomerase-I antibody in the serum of any of these SLE patients.
In conclusion, SLE is a complex disease with obviously complicated genetics. Here we demonstrate that stratifying lupus patients based on a relatively uncommon immunologic feature in SLE isolates a genetic effect to the extent that it reveals an impressive genetic linkage. If this is generally true for SLE, then there must be many genetic effects in this disease awaiting discovery.
Methods
Patients and pedigrees SLE patients and their family members were enrolled in the lupus genetics studies when two or more pedigree members whose relationship was potentially useful for linkage also fulfilled at least four of the American College of Rheumatology criteria. 4, 5 Medical information was collected both from medical records and from a questionnaire and interview. A total of 160 pedigrees multiplex for lupus in five cohorts (A, B, C, 1 and 2) were enrolled and genotyped at 307 genetic markers. Of the 160 lupus pedigrees in the collection, 27 had at least one SLE affected patient with nucleolar fluorescence on antinuclear antibody test using the human tumor cell line HEp-2 ( Table 2) . (3) 28 (2) 55 (1) 5 (0) The number of individuals with anti-nucleolar antibodies are presented in parentheses.
Genes and Immunity
Statistical analysis
A matched case-control study for the association with the ACR criteria was performed. The control group consisted of 78 SLE patients who did not have nucleolar antinuclear antibody and who were not blood relatives of the nucleolar antinuclear antibody SLE patients. In both the cases and the controls, only one patient per family was included in the analysis to exclude any family-dependent data. A 1:3 match on race and sex was made. Manual conditional logistic regression was used to compute adjusted odds ratios for any associations with the 11 ACR criteria between these two groups. Independent variables included discoid rash, malar rash, oral ulcers, photosensitivity, arthritis, leukopenia, lymphopenia, thrombocytopenia, antibodies to dsDNA, Sm, IgG and IgM anticardiolipin, antinuclear antibodies, seizures, psychosis, cellular casts, proteinuria, pericarditis and pleuritis. The dependent variable was nucleolar antinuclear antibody pattern. All of the variables were dichotomous. Lupus anticoagulant, false positive VDRL, and LE cell were not used in the analyses due to a large amount of missing data.
Genotyping
Genomic DNA was isolated from peripheral blood mononuclear cells, buccal cell swabs, or lymphoblastoid cell lines using conventional methods, as previously described. 15 A total of 307 microsatellite markers were typed from the version 8 Weber screening set (http://research.marshfieldclinic.org/genetics/sets/Set8 ScreenFrames.htm), which has an average marker spacing of 11 cM. Polymerase chain reactions were performed as previously described. 15 Amplified fragments were detected using 6% polyacrylamide gels on automated Licor Model 4000 DNA sequencers. Gel images were collected using Base ImagIR software, version 4.0, and alleles were determined using Gene ImagIR, version 3.52. Twenty pedigrees were initially genotyped by the Mammalian Genotyping Center in Marshfield, WI (http://research.marshfieldclinic.org/genetics/), using a fluorescent-based detection system.
Linkage analysis
Prior to any linkage analysis, sibling, half-sibling, and parent-offspring relationships were confirmed using statistics generated by RELTEST, a feature of the S.A.G.E. 4.0 package, version Beta 3. 18, 19 Two-point LOD scores were calculated using FASTLINK, version 4.1p and the ANALYZE package. [20] [21] [22] Six inheritance models were used for screening analysis as described previously. 7 Multipoint linkage analysis was done using the GENEHUNTER-PLUS program. 
